Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Retinal vein occlusion is a blockage of a vein that drains blood from the retina, the light-sensing tissue at the back of the eye. When a central vein (CRVO) or a branch vein (BRVO) is obstructed, pressure rises, blood and fluid leak, and the macula may swell. People often notice painless blurry vision or a sudden smudge in one eye.
read more about retinal vein occlusion ...RVO can threaten central vision if macula swelling or poor blood flow develops, and severe ischemic CRVO can lead to abnormal vessel growth and glaucoma. Many patients improve with treatment, but close follow-up is needed because swelling can recur and new vessels may form months later. Early diagnosis and timely therapy reduce the chance of permanent loss.
RVO usually results from a blood clot forming where an artery and vein cross in the retina or within the main retinal vein. Age, high blood pressure, diabetes, high cholesterol, glaucoma, and smoking increase risk. Vessel wall damage and sluggish blood flow promote clotting.
Less commonly, clotting disorders, inflammation, or medications that affect blood thickness are involved. Because RVO can flag systemic disease, doctors often coordinate with primary care to optimize blood pressure, blood sugar, and cholesterol control.
Symptoms range from mild blur to a sudden loss of central detail in one eye. Some notice distorted or washed-out vision. Floaters can appear if bleeding reaches the gel inside the eye. Pain is uncommon unless abnormal vessel growth and glaucoma develop.
On exam, doctors may see retinal bleeding, dilated twisted veins, cotton-wool spots, and macula swelling. Severe CRVO shows extensive bleeding and poor perfusion on imaging, which raises the risk of complications.
RVO can reduce reading and driving vision through macula swelling or poor blood flow, and severe CRVO may lead to abnormal vessel growth and glaucoma without surveillance. People with sudden painless blur in one eye should be examined promptly so treatment can begin early and risk factors can be addressed.
The outlook is often good with a structured plan. Anti-VEGF therapy can restore or stabilize vision, and laser or steroids are available for selected scenarios. Pairing eye care with blood pressure, blood sugar, and cholesterol control helps prevent recurrence and supports long-term eye health. Regular follow-up with imaging allows timely retreatment if swelling returns.
References
Cleveland Clinic. Retinal Vein Occlusion: Causes, Types & Treatment. https://my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo
National Eye Institute. Central Retinal Vein Occlusion (CRVO). https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/central-retinal-vein-occlusion-crvo
American Academy of Ophthalmology. What Is a Retinal Vein Occlusion? https://www.aao.org/eye-health/diseases/retinal-vein-occlusion-3
AAO Preferred Practice Pattern. Retinal Vein Occlusions. https://www.aaojournal.org/article/S0161-6420(19)32096-2/fulltext
FDA. LUCENTIS (ranibizumab) label, indication for RVO macular edema. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf
FDA. EYLEA (aflibercept) label, indication for RVO macular edema. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125387s069lbl.pdf
PubMed. BRAVO and CRUISE trials of ranibizumab for RVO. https://pubmed.ncbi.nlm.nih.gov/22817833/
NIH NEI News. Vision improvement is long-lasting with treatment for RVO. https://www.nei.nih.gov/news-events/news-releases/vision-improvement-long-lasting-treatment-blinding-blood-vessel-condition
EyeWiki. Retinal Vein Occlusion. https://eyewiki.org/Retinal_Vein_Occlusion
MedlinePlus. Retinal vein occlusion. https://medlineplus.gov/ency/article/007330.htm
Diagnosis includes a dilated retinal exam, optical coherence tomography to detect macula swelling, and fluorescein angiography or advanced imaging to map leakage and areas of poor blood flow. Blood pressure, blood sugar, and cholesterol are reviewed, and glaucoma is assessed.
Treatment focuses on macula swelling and abnormal vessel growth. Anti-VEGF injections are first-line for vision-threatening swelling in both BRVO and CRVO, supported by clinical trials and FDA approval. Steroid injections or implants are options in selected cases. Laser treatment addresses areas of abnormal vessels or, in BRVO, can be used for persistent swelling in specific patterns. Ongoing monitoring guides the timing and duration of therapy.
It is a blockage in an eye vein, sometimes called an eye stroke in lay terms, but it is not a brain stroke. Because shared risk factors exist, cardiovascular evaluation is still important.
RVO itself does not determine life expectancy, but it signals systemic risks that should be managed with primary care to protect overall health.
Yes. Many patients gain vision with anti-VEGF therapy for macula swelling, though some need long-term monitoring and repeat treatment.